
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
1 August 2022
One Cancer Voice writes to Sajid Javid ahead of 10-Year Cancer Plan
Today, with over 50 cancer charities, we wrote to the Secretary of State for Health & Social Care, Sajid Javid, to set out our expectation for next month’s 10-Year Cancer Plan….
12 December 2022
Widespread coverage of new leukaemia therapy shows promise in first trial patient
As you may have seen in the news over the weekend, a clinical trial investigating a new leukaemia treatment has shown promising results. As part of the trial, funded by…
27 September 2024
Leukaemia UK calls upon government to increase blood testing capacity
Together with Leukaemia Care, we’re calling on the new Secretary of State for Health and Social Care to focus on ‘business as usual’ primary care testing alongside innovation, amid concerns…
11 February 2022
International Childhood Cancer Day: Dr Samanta Mariani reflects on her research into infant leukaemia
On International Childhood Cancer Day, Dr Samanta Mariani reflects on her research into infant leukaemia, what drives her in her work and her hopes for the future.